Pharmaceutical - Pharmaceutical, Teva Pharmaceutical Industries

Filter

Popular Filters

1 to 25 of 6904 results

Jacques Servier, founder and president of Lab Servier, dies aged 92

17-04-2014

French independent drugmaker Laboratories Servier announced that its founder and president, Jacques Servier,…

BoardroomManagementPharmaceuticalServier

GSK confirms further misconduct allegations, now in Jordan and Lebanon

17-04-2014

There has been recent publicity on cases of alleged misconduct by UK Pharma giant GlaxoSmithKline employees…

GlaxoSmithKlineJordanMarkets & MarketingPharmaceuticalRegulationRest of the World

Teva and Pfizer settle patent litigation over Celebrex

17-04-2014

Israel-based Teva Pharmaceutical Industries says that its US subsidiary has settled a law suit with US…

Anti-Arthritics/RheumaticsCelebrexGenericsNorth AmericaPatentsPfizerTeva Pharmaceutical IndustriesUSA

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients

17-04-2014

US health care company Baxter International as released encouraging top-line results from a Phase III…

BAX 111Baxter InternationalHematologyPharmaceuticalResearch

SI Group acquires ibuprofen and antioxidants from Albemarle Corp

SI Group acquires ibuprofen and antioxidants from Albemarle Corp

17-04-2014

Family-owned US chemical developer and manufacturer SI Group has signed a deal to acquire the antioxidants,…

AlbemarleAnalgesiaibuprofenMergers & AcquisitionsPharmaceuticalUSA

Free drug samples can change prescribing habits of US dermatologists

17-04-2014

The availability of free medication samples in dermatology offices in the USA appears to change prescribing…

DermatologicalsMarkets & MarketingPharmaceuticalUSA

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

17-04-2014

British charity Cancer Research UK has joined forces with Anglo-Swedish drug major AstraZeneca and US…

AstraZenecaCancerHealthMajorMedicineOncologyPfizerPharmaceuticalPharmacologyResearchUK

Astellas settles with US DoJ over Mycamine marketing

Astellas settles with US DoJ over Mycamine marketing

17-04-2014

The US subsidiary of Japanese drug major Astellas Pharma will pay $7.3 million to resolve allegations…

Antibiotics and Infectious diseasesAstellas PharmaLegalMarkets & MarketingMycamineNorth AmericaPharmaceuticalUSA

EMA says that vials of falsified Herceptin have been identified

EMA says that vials of falsified Herceptin have been identified

16-04-2014

The European Medicines Agency says it has been informed that vials of Swiss drug major Roche’s blockbuster…

EuropeHealthcareHerceptinOncologyPharmaceuticalRegulationRoche

Astellas US promotes Jeffrey Bloss to SVP of medical affairs for the Americas

Astellas US promotes Jeffrey Bloss to SVP of medical affairs for the Americas

16-04-2014

The US subsidiary of Japanese drug major Astellas Pharma announced that Jeffrey Bloss has been promoted…

Astellas PharmaBoardroomManagementPharmaceuticalUSA

Teva and Dr Reddy’s latest to launch generic Lunesta in USA

16-04-2014

Two more companies have debuted generic versions of the insomnia drug Lunesta (eszopiclone) tablets,…

Dainippon Sumitomo PharmaDr Reddy's LaboratoriesGenericsLunestaMarkets & MarketingNeurologicalNorth AmericaSunovion PharmaceuticalsTeva Pharmaceutical IndustriesUSA

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

16-04-2014

Surveyed neurologists in France, Germany, Italy, Spain and the UK project that 16% of their diagnosed…

AubagioBiogen IdecChemistryCNS DiseasesEuropeGenzymeMajorPharmaceuticalPharmacologyPhysicianResearchSANTecfidera

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

16-04-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget today announced their intention…

belinostatBioAlliance PharmaLivatagMergers & AcquisitionsOncologyPharmaceuticalRare diseasesTopotarget

Drug developers using new models and methods to boost clinical success rates

16-04-2014

Drug companies and their development partners who are seeking to increase clinical success rates of new…

ManagementPharmaceuticalResearch

OxThera gains $10 million investment to continue Phase II trial

16-04-2014

Shareholders of privately-held Swedish biopharmaceutical company OxThera have agreed with a syndicate…

BiopharmaceuticalFinancialKidney diseasesOxabactOxTheraPharmaceuticalPrimary hyperoxaluriaRare diseasesRemi DrollerSweden

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes

16-04-2014

UK pharma giant GlaxoSmithKline yesterday received the much anticipated approval from the US Food and…

albiglutideDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationTanzeumUSA

Johnson & Johnson 1st-qtr 2014 results beat expectations

Johnson & Johnson 1st-qtr 2014 results beat expectations

15-04-2014

US health care giant Johnson & Johnson today reported financial results for the first quarter of 2014,…

FinancialJohnson & JohnsonPharmaceutical

$5 million milestone for India’s Glenmark from Sanofi

$5 million milestone for India’s Glenmark from Sanofi

15-04-2014

Indian drugmaker Glenmark Pharmaceuticals says it has informed the Stock Exchange that it has received…

FinancialGlenmark PharmaceuticalsInflammatory diseasesPharmaceuticalResearchSanofi

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

15-04-2014

German family-owned drug major Boehringer Ingelheim today posted financial results for 2013, noting that,…

Boehringer IngelheimFinancialPharmaceutical

1 to 25 of 6904 results

Company Spotlight

Fibrotech

Fibrotech

Back to top